Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration With Gates Institute At University Of Colorado Anschutz Medical Campus
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories (NYSE:CRL) has announced a strategic collaboration with the Gates Institute at the University of Colorado Anschutz Medical Campus to develop GMP-grade lentiviral vectors for CAR T-cell therapies targeting hematological cancers.
June 25, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories has entered into a strategic collaboration with the Gates Institute to develop GMP-grade lentiviral vectors for CAR T-cell therapies targeting hematological cancers.
The collaboration with the Gates Institute enhances Charles River Laboratories' position in the cell and gene therapy market, potentially leading to increased demand for its services and a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100